Technology Listings


108 Results Sort By:
Combination Therapy to Overcome Resistance to Platinum-Based Chemotherapy
Application MAST1 inhibitors to overcome resistance to platinum-based chemotherapy, exacerbated by dexamethasone co-administration. Key Benefits Co-administration of MAST1 inhibitor and MAST1-stabilizing protein inhibitor abrogates tumor resistance to cisplatin MAST1 inhibitor, lestaurtinib, has previously reached phase III clinical trials and...
Published: 8/25/2021       Contributor(s): Sumin Kang, Jing Chen
Automated Multiple Needle Detection For Brachytherapy
Application Workflow to detect multiple needles in three-dimensional ultrasound images. Key Benefits Does not require specialized ultrasound pulses or hardware. Detects multiple needles with low error. Market Summary Many minimally invasive procedures require inserting a needle to access a target site inside the patient body, avoiding the requirement...
Published: 11/2/2020       Contributor(s): Xiaofeng Yang, Tian Liu, Yupei Zhang, Pretesh Patel
Amino Acid-Derived Radiotracer Compounds for PET Cancer Imaging
Application New class of fluorine-18 labeled amino acid-derived radiotracer compounds for positron emission tomography (PET) cancer imaging. Key Benefits Next generation of cancer imaging agents. Enhanced sensitivity to detect glioblastoma, prostate cancer and other cancers. Market Summary PET imaging is a type of nuclear medicine procedure...
Published: 11/2/2020       Contributor(s): Mark Goodman, Lanny Liebeskind, Thomas Pickel
Photocaged Cytokines for Cancer Immunotherapy
Application Light-responsive cytokine prodrugs with controlled activation for improved cancer immunotherapy. Key Benefits Prolonged circulation and biased immune cell-selectivity. Controlled local activation, reduces off-target toxicity. Requires less frequent dosing. Market Summary While recombinant cytokines hold great potential for cancer...
Published: 11/2/2020       Contributor(s): Erik Dreaden, Lacey Perdue, Priscilla Do
PNP-based Solid Tumor Therapy in Conjunction with Checkpoint Blockade Inhibitors
Application Treatment of solid tumors combining purine nucleoside phosphorylase (PNP) technology with checkpoint blockade inhibition. Key Benefits Safe and effective method for markedly enhancing checkpoint blockade therapy for refractory tumors. Checkpoint inhibitor therapy is FDA-approved and already in use. Market Summary Checkpoint blockade...
Published: 10/22/2020       Contributor(s): Eric Sorscher, Turang Behbahani, Regina Rab, Annette Ehrhardt, Jeong Hong, Disha Joshi
Galectin-9 Directed CAR T-cells for Overcoming Resistance to Chemotherapy in Hematological Malignancies
Application Anti-human Galectin-9-directed chimeric antigen receptor (CAR) T-cells for treatment of hematological malignancies (B-ALL, T-ALL, and DLBCL) in normal, overweight, and obese patients. Key Benefits Can be used as a stand-alone or in-combination product to treat patients with hematological malignancies, particularly overweight and obese...
Published: 10/13/2020       Contributor(s): Curtis Henry, Miyoung (Mi-Young) Lee, Sunil Raikar, Jamie Hamilton, Anthony Ross
Class of Bcl-2 Inhibitors as Anti-Cancer Therapeutics
Application Small molecule inhibitors of Bcl-2, an anti-apoptotic protein, for cancer treatment. Key Benefits Developed specifically to target the BH4 homology domain of Bcl-2 in order to improve binding affinity and anti-tumor efficacy over other Bcl-2 inhibitors. Compounds may simultaneously suppress a wider range of anti-apoptotic proteins than...
Published: 10/2/2020       Contributor(s): Xingming Deng, Jia Zhou, Chunyong Ding
Development of Bax Activators as a New Class of Anti-Cancer Drugs
Application Therapeutic for treatment of cancer. Key Benefits The first in class, potent and selective agonists of Bax with nanomolar activity. Bax activators have significantly less apoptotic effect on normal cells as compared to cancer cells. Compounds have shown high selectivity for tumor cells. Technical Summary Patients with cancer have...
Published: 10/2/2020       Contributor(s): Xingming Deng, Jia Zhou, Chunyong Ding
Drug Combination to Treat Lung Cancer Metastasis
Application Combination product co-targeting PDH and GLUT1 to inhibit lung cancer metastasis. Key Benefits Combination of drugs exhibits greater synergism in cancer cell lines (H1299, 4T1, H1792). Has potential to prevent metastasis in a variety of cancers. Decreases both cell viability and invasive area. Repurposed drugs. Market Summary Lung...
Published: 10/1/2020       Contributor(s): Malathy (mala) Shanmugam, Adam Marcus
Small Molecule Inhibitor of Akt Activity for Lung Cancer Treatment
Application Mcl-1/Akt targeting small molecule with strong antitumor activity against lung cancer. Key Benefits Novel molecule. Novel target presents new path to lung cancer treatment. Potentially extend survival rate of lung cancer patients. Market Summary Lung cancer is the number one leading cause of death among cancer patients. Patients...
Published: 4/17/2020       Contributor(s): Xingming Deng
1 2 3 4 5 6 7 8 9 10 ...